Early Administration of Anti-SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients.
COVID-19
monoclonal antibody
transplantation
viral infection
Journal
Kidney international reports
ISSN: 2468-0249
Titre abrégé: Kidney Int Rep
Pays: United States
ID NLM: 101684752
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
18
02
2022
revised:
18
03
2022
accepted:
21
03
2022
pubmed:
5
4
2022
medline:
5
4
2022
entrez:
4
4
2022
Statut:
ppublish
Résumé
Kidney transplant recipients (KTRs) are prone to develop severe COVID-19 and are less well protected by vaccine than immunocompetent subjects. Thus, the use of neutralizing anti-SARS-CoV-2 monoclonal antibody (MoAb) to confer a passive immunity appears attractive in KTRs. We performed a French nationwide study to compare COVID-19-related hospitalization, 30-day admission to intensive care unit (ICU), and 30-day death between KTRs who received an early infusion of MoAb (MoAb group) and KTRs who did not (control group). Controls were identified from the COVID-SFT registry (NCT04360707) using a propensity score matching with the following covariates: age, sex, delay between transplantation and infection, induction and maintenance immunosuppressive therapy, initial symptoms, and comorbidities. A total of 80 KTRs received MoAb between February 2021 and June 2021. They were matched to 155 controls. COVID-19-related hospitalization, 30-day admission to ICU, and 30-day death were less frequently observed in the MoAb group (35.0% vs. 49.7%, The early use of MoAb in KTRs with a mild form of COVID-19 largely improved outcomes in KTRs.
Identifiants
pubmed: 35372734
doi: 10.1016/j.ekir.2022.03.020
pii: S2468-0249(22)01240-2
pmc: PMC8957354
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1241-1247Informations de copyright
© 2022 International Society of Nephrology. Published by Elsevier Inc.
Références
Am J Transplant. 2021 Mar;21(3):1295-1303
pubmed: 33259686
N Engl J Med. 2021 Sep 23;385(13):1244-1246
pubmed: 34379917
N Engl J Med. 2021 Nov 18;385(21):1941-1950
pubmed: 34706189
Science. 2021 Sep 03;373(6559):1109-1116
pubmed: 34344823
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Am J Transplant. 2021 Dec;21(12):4043-4051
pubmed: 34431207
N Engl J Med. 2021 Sep 23;385(13):1184-1195
pubmed: 34347950
JAMA. 2021 May 4;325(17):1784-1786
pubmed: 33720292
Kidney Int. 2021 Aug;100(2):477-479
pubmed: 34029554
Clin Transplant. 2021 Apr;35(4):e14245
pubmed: 33595145
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Am J Transplant. 2021 Mar;21(3):1285-1294
pubmed: 33252201
J Infect Dis. 2021 Oct 28;224(8):1278-1286
pubmed: 34279629
N Engl J Med. 2021 Jan 21;384(3):229-237
pubmed: 33113295
Vaccines (Basel). 2021 Sep 23;9(10):
pubmed: 34696163
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
N Engl J Med. 2021 Aug 12;385(7):661-662
pubmed: 34161700
Am J Transplant. 2022 Jan;22(1):322-323
pubmed: 34331842
Cell. 2021 Apr 15;184(8):2183-2200.e22
pubmed: 33756110
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
BMJ. 2021 Mar 9;372:n579
pubmed: 33687922
Cell Rep. 2021 Jul 20;36(3):109415
pubmed: 34270919
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
Cell Host Microbe. 2021 Jul 14;29(7):1162-1162.e1
pubmed: 34265246
Transplantation. 2021 Oct 1;105(10):e146-e147
pubmed: 34224543
Pharmacotherapy. 2021 Sep;41(9):743-747
pubmed: 34328670
Open Forum Infect Dis. 2021 Jun 23;8(7):ofab331
pubmed: 34327256
Kidney Int. 2021 Jun;99(6):1487-1489
pubmed: 33775674
Kidney Int. 2020 Dec;98(6):1549-1558
pubmed: 32853631
Transplantation. 2021 Jul 1;105(7):e68-e69
pubmed: 33724242
Viruses. 2021 Jun 23;13(7):
pubmed: 34201591
Transpl Infect Dis. 2021 Oct;23(5):e13662
pubmed: 34081820
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246